Table 1 Clinical and molecular features of patients.
Patient id | Age (years) | Histology | Radical prostatectomy and/or radiotherapy | Primary ADT | Number of therapies before CTC collection | Type of tp at time of CTC collection | Serum CGA and /or NSE | Serum PSA (ng/ml) | Presence of visceral metastasis | Number of TSG (no = 0, single = 1, double = 2, triple = 3) |
|---|---|---|---|---|---|---|---|---|---|---|
10 | 79 | Adeno-NE | No | Yes | 2 | Cisplatin etoposide | High | 0.18 | Yes | 1 |
11 | 62 | CRPC-Adeno | Yes | Yes | 3 | Abiraterone | Normal | 165 | No | 0 |
12 | 69 | Small cell | No | Yes | 1 | Cisplatin | High | 0.01 | Yes | 2 |
26 | 68 | Small cell | Yes | Yes | 3 | Aurora A kinase inhibitor | High | 0.008 | Yes | 2 |
31 | 74 | Adeno-NE | No | Yes | 2 | Carboplatin etoposide | High | 1.39 | Yes | 3 |
33 | 68 | CRPC-Adeno | Yes | Yes | 4 | Docetaxel | Normal | 329 | No | 1 |
35 | 59 | Adeno-NE | Yes | No | 1 | Cisplatin etoposide | High | 0.98 | No | 2 |
36 | 70 | Adeno-NE | Yes | Yes | 5 | Rovalpituzumab tesirine | High | 0.06 | Yes | 1 |
37 | 58 | CRPC-Adeno | No | Yes | 2 | Enzalutamide | Normal | 27.2 | No | 0 |
38 | 79 | Adeno-NE | Yes | Yes | 1 | Cisplatin etoposide | High | 0.02 | Yes | 2 |
41 | 65 | CRPC-Adeno | Yes | Yes | 4 | Enzalutamide | Normal | 7.85 | No | 1 |
